Innate Pharma Enrolls Patients in Clinical Trial for Cancer Tumor Therapy

MT Newswires · 4d ago
01:40 AM EDT, 07/21/2026 (MT Newswires) -- Innate Pharma SA (IPH.PA) completed patient enrollment for the dose-escalation part of its initial-stage study to evaluate its Nectin-4 exatecan antibody-drug conjugate, IPH4502, in treating advanced solid tumors in several malignancies. The oncology-focused biotechnology company enrolled 76 patients in France and the US for the dose escalation under its PH4502-101 phase 1 study, according to a Tuesday release. The preliminary results from the dose-escalation part of the study are expected by the end of 2026.